Halozyme Therapeutics Inc
F:RV7
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
H
|
Halozyme Therapeutics Inc
F:RV7
|
US |
|
F
|
Ford Motor Co
F:FMC1
|
US |
|
E
|
Eli Lilly and Co
XMUN:LLY
|
US |
|
C
|
Cisco Systems Inc
F:CIS
|
US |
|
Continental AG
XETRA:CON
|
DE |
|
Chocoladefabriken Lindt & Spruengli AG
SIX:LISN
|
CH |
|
HEICO Corp
NYSE:HEI
|
US |
|
L
|
Laureate Education Inc
F:LA3A
|
US |
Wall St Price Targets
RV7 Price Targets Summary
Halozyme Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for RV7 is 75.55 EUR with a low forecast of 50.04 EUR and a high forecast of 87.61 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is RV7's stock price target?
Price Target
75.55
EUR
According to Wall Street analysts, the average 1-year price target for RV7 is 75.55 EUR with a low forecast of 50.04 EUR and a high forecast of 87.61 EUR.
What is the Revenue forecast for Halozyme Therapeutics Inc?
Projected CAGR
0%
Over the last 14 years, the compound annual growth rate for Revenue has been 26%. The projected CAGR for the next 8 years is 0%.
What is the Operating Income forecast for Halozyme Therapeutics Inc?
Projected CAGR
-5%
The compound annual growth rate for Operating Income over the next 8 years is -5%.
What is the Net Income forecast for Halozyme Therapeutics Inc?
Projected CAGR
10%
The compound annual growth rate for Net Income over the next 8 years is 10%.
